Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study
Objective To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.Design Nationwide, population-based cohort study using real-world data.Setting The study used national health...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/6/e058898.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590085461114880 |
|---|---|
| author | Christian Torp-Pedersen Mette Nørgaard Helle D Zacho Lars J Petersen Anna Winther Mogensen Marie T Pank |
| author_facet | Christian Torp-Pedersen Mette Nørgaard Helle D Zacho Lars J Petersen Anna Winther Mogensen Marie T Pank |
| author_sort | Christian Torp-Pedersen |
| collection | DOAJ |
| description | Objective To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.Design Nationwide, population-based cohort study using real-world data.Setting The study used national health registries, including all sites in Denmark from 2011 to 2018.Participants Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. Patients were stratified into two groups according to the preoperative imaging modality of either 18F-NaF PET or bone scintigraphy.Main outcome measures The risk of skeletal-related events (SREs) as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.Results Between 1 January 2011 and 31 December 2018, 4183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent 18F-NaF PET and 2161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the HR of experiencing an SRE for patients in the 18F-NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86 to 1.54). The 3-year survival rates were 97.4% (95% CI 96.1 to 98.7) and 97.1% (95% CI 96.4 to 97.9) for patients receiving 18F-NaF PET and bone scintigraphy, respectively.Conclusion Patients with high-risk prostate cancer undergoing preoperative staging with 18F-NaF PET did not display a lower risk of developing SREs after prostatectomy compared with patients undergoing bone scintigraphy. The survival rates were similar between the two groups. |
| format | Article |
| id | doaj-art-e244c3db86814616a2625ab63283b8f6 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-e244c3db86814616a2625ab63283b8f62025-01-24T03:30:15ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2021-058898Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort studyChristian Torp-Pedersen0Mette Nørgaard1Helle D Zacho2Lars J Petersen3Anna Winther Mogensen4Marie T Pank53 Department of Cardiology and Clinical Research, Nordsjællands Hospital, Hillerød, DenmarkDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Nuclear Medicine, Aalborg University Hospital, Aalborg, DenmarkDepartment of Nuclear Medicine, Aalborg University Hospital, Aalborg, DenmarkDepartment of Nuclear Medicine, Aalborg University Hospital, Aalborg, DenmarkDepartment of Urology, Aalborg University Hospital, Aalborg, DenmarkObjective To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.Design Nationwide, population-based cohort study using real-world data.Setting The study used national health registries, including all sites in Denmark from 2011 to 2018.Participants Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. Patients were stratified into two groups according to the preoperative imaging modality of either 18F-NaF PET or bone scintigraphy.Main outcome measures The risk of skeletal-related events (SREs) as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.Results Between 1 January 2011 and 31 December 2018, 4183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent 18F-NaF PET and 2161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the HR of experiencing an SRE for patients in the 18F-NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86 to 1.54). The 3-year survival rates were 97.4% (95% CI 96.1 to 98.7) and 97.1% (95% CI 96.4 to 97.9) for patients receiving 18F-NaF PET and bone scintigraphy, respectively.Conclusion Patients with high-risk prostate cancer undergoing preoperative staging with 18F-NaF PET did not display a lower risk of developing SREs after prostatectomy compared with patients undergoing bone scintigraphy. The survival rates were similar between the two groups.https://bmjopen.bmj.com/content/12/6/e058898.full |
| spellingShingle | Christian Torp-Pedersen Mette Nørgaard Helle D Zacho Lars J Petersen Anna Winther Mogensen Marie T Pank Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study BMJ Open |
| title | Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study |
| title_full | Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study |
| title_fullStr | Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study |
| title_full_unstemmed | Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study |
| title_short | Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study |
| title_sort | use of 18f naf pet in the staging of skeletal metastases of newly diagnosed high risk prostate cancer patients a nationwide cohort study |
| url | https://bmjopen.bmj.com/content/12/6/e058898.full |
| work_keys_str_mv | AT christiantorppedersen useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy AT mettenørgaard useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy AT helledzacho useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy AT larsjpetersen useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy AT annawinthermogensen useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy AT marietpank useof18fnafpetinthestagingofskeletalmetastasesofnewlydiagnosedhighriskprostatecancerpatientsanationwidecohortstudy |